Univariate (P = 0.015) and multivariate (P = 0.038) COX analyses unveiled that upregulated CMTM6 protein expression was one of the independent risk factors for the development of trastuzumab-resistance in patients with HER2+ BC (Tables 2 and 3). This evidence concerns the gene ERBB2 and breast cancer.